We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+19.23%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$140M
AUM Growth
+$21.9M
Cap. Flow
+$4.55M
Cap. Flow %
3.25%
Top 10 Hldgs %
48%
Holding
83
New
9
Increased
22
Reduced
16
Closed
8

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$2.79M
2
IMMU
Immunomedics Inc
IMMU
+$2.7M
3
DERM
Dermira, Inc.
DERM
+$1.44M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.44M
5
NERV icon
Minerva Neurosciences
NERV
+$1.42M

Top Sells

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$2.61M
2
TVRD
Tvardi Therapeutics
TVRD
+$1.75M
3
NVDQ
Novadaq Technologies Inc.
NVDQ
+$747K
4
MTVA
MetaVia Inc
MTVA
+$725K
5
ABEO icon
Abeona Therapeutics
ABEO
+$338K

Sector Composition

Rank Sector Weight
1 Healthcare 80.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CASC
51
DELISTED
Cascadian Therapeutics, Inc.
CASC
$436K 0.31%
117,310
-67,949
-37% -$270K
MTVA
52
MetaVia Inc
MTVA
$8.68M
– –
-1
Closed -$725K
MASI
53
DELISTED
Masimo
MASI
$388K 0.28%
4,250
+750
+21% +$68.9K
SRRA
54
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$310K 0.22%
6,625
– –
NTUS
55
DELISTED
Natus Medical Inc
NTUS
$295K 0.21%
+7,900
New +$285K
HSTO
56
DELISTED
Histogen Inc. Common Stock
HSTO
$288K 0.21%
+250
New +$304K
EIGR
57
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$284K 0.2%
1,199
– –
ARNA
58
DELISTED
Arena Pharmaceuticals Inc
ARNA
$262K 0.19%
+15,550
New +$213K
BLCM
59
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$234K 0.17%
2,000
– –
FSTX
60
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$217K 0.15%
+400
New +$18.5K
OBSV
61
DELISTED
ObsEva SA Ordinary Shares
OBSV
$214K 0.15%
25,000
– –
PDSB icon
62
PDS Biotechnology
PDSB
$40.1M
$199K 0.14%
+970
New +$191K
AFMD
63
DELISTED
Affimed
AFMD
$190K 0.14%
9,250
– –
ARRY
64
DELISTED
Array Biopharma Inc
ARRY
$167K 0.12%
+20,000
New +$164K
ANAB icon
65
AnaptysBio
ANAB
$1.49B
$132K 0.09%
5,500
+1,000
+22% +$25.1K
DMK
66
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$127K 0.09%
349
-80
-19% -$24K
CBAY
67
DELISTED
Cymabay Therapeutics
CBAY
$110K 0.08%
19,067
-69,000
-78% -$294K
TRIL
68
DELISTED
Trillium Therapeutics Inc.
TRIL
$88K 0.06%
+20,000
New +$111K
SLS icon
69
SELLAS Life Sciences
SLS
$2.45B
$27K 0.02%
31
– –
ABEO icon
70
Abeona Therapeutics
ABEO
$369M
– –
-2,701
Closed -$338K
AXSM icon
71
Axsome Therapeutics
AXSM
$11.4B
– –
-55,700
Closed -$217K
TNXP icon
72
Tonix Pharmaceuticals
TNXP
$175M
– –
0
– -$93K
PVLA
73
Palvella Therapeutics
PVLA
$1.78B
– –
-669
Closed -$139K
TVRD
74
Tvardi Therapeutics
TVRD
$27.5M
– –
-2,648
Closed -$1.75M
CYAD
75
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
– –
-12,528
Closed -$328K
1 2
3
4

Similar funds

FGWP
Founders Grove Wealth Partners Richmond, Virginia $440M AUM 16.56% 1-Year Est. Return
CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
AWM
Austin Wealth Management Austin, Texas $440M AUM 17.66% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return

DAFNA Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, DAFNA Capital Management held 83 positions worth $140M, up 19% from $118M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $4.55M of net new capital in Q2 2017, opening 9 new positions and adding to 22 existing holdings. Its largest new stake was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was AtriCure, an estimated $2.61M trimmed.

  • DAFNA Capital Management's largest Q2 2017 buy was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.
  • DAFNA Capital Management added most to Aerie Pharmaceuticals in Q2 2017, an estimated $2.79M increase.
  • DAFNA Capital Management's biggest Q2 2017 reduction was AtriCure, cutting an estimated $2.61M.
  • DAFNA Capital Management fully exited Tvardi Therapeutics in Q2 2017, selling an estimated $1.75M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $140M portfolio in Q2 2017.
  • DAFNA Capital Management opened 9 new positions and closed 8 in Q2 2017.
  • DAFNA Capital Management's portfolio value rose 19% quarter-over-quarter to $140M.

Based on DAFNA Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.